Medtronic sees Q4 EPS $1.44-$1.46, consensus $1.45

Says sees unfavorable 5% impact on EPS in Q4. Says expects to increase R&D investments. Says exiting unprofitable ventilator product line. Says market is shifting to lower acuity ventilators. Says seeing a lot of enthusiasm for PFA products. Says submitted Evolut FX+ to FDA for approval. Says adjusted tax rate was higher than expected. Comments and guidance taken from Q3 earnings conference call.